Abstract: The disclosure relates to therapeutic methods or methods of treating, clearing, preventing or curing Human Immunodeficiency Virus (HIV) infection. The disclosure provides a combination of at least one agent selected from the group consisting of: fostemsavir and temsavir, or a pharmaceutically acceptable salt thereof and a CD4 binding site (CD4bs) binding protein for the use in treatment of HIV and/or clearance of HIV infected cells.

Abstract: A flowmeter (5) is provided having a sensor assembly (10) connected to meter electronics (20), wherein the sensor assembly (10) comprises at least one driver (104) and at least one pickoff (105) and a variably modulated conduit (300) configured to change a flow area (304) therein.

Abstract: A flowmeter (5) is provided having a sensor assembly (10) connected to meter electronics (20), wherein the sensor assembly (10) comprises at least one driver (104) and at least one pickoff (105) and a variably modulated conduit (300) configured to change a flow area (304) therein.

Abstract: A threat fire simulation system (40) for simulating a projectile impacting a user (26) includes an electrical impulse element (44) configured for physical contact with the user (26). A controller (42) is in communication with the electrical impulse element (44). The controller (42) enables receipt of a signal (54) for activating electrical impulse element (44) to deliver a non-disabling electrical pulse (46) to the user (26). The electrical pulse (46) simulates an impact of the projectile on the user (26).

Abstract: A simulation system (20) facilitates training for trainees (26) subject to multi-directional threats. A method for providing a scenario (211) for use in the simulation system (20) utilizes a scenario provision process (202) executable on a computing system (26). The process (202) calls for choosing a background image (234) for the scenario (211), and selecting a video clip(s) (386) of one or more actors (266) from a database (203) of video clips (386). The video clip(s) (386) are filmed using a green or blue screen technique, and include a mask portion (394) of the actor (266) and a transparent portion (396). The video clip(s) (386) are combined with the background image (234) to create the scenario (211), with the mask portion (394) forming a foreground image over the background image (234). The scenario (211) is displayed on a display of the simulation system (20).

Abstract: Highly stable pharmaceutical compositions suitable for parenteral administration to animals or humans comprising a therapeutically effective amount of an RTA-immunoconjugate dissolved in an inert carrier method comprising a stabilizer are claimed. Screening methods for selecting stabilizers effective in preventing precipitation and aggregation of such compositions are described. Preferred stabilizers includes glycerol at a concentration (v/v) of from about 25 to about 35%; dextran sulfates having molecular weights from about 0.1.times.10.sup.6 to about 2.times.10.sup.6 daltons; and human serum albumin.The invention further comprises such compositions which have been lyophilized and/or reconstituted wherein the stabilizer is non-volatile, and may further comprise a carbohydrate stabilizer.The invention further comprises stabilized RTA compositions.

Abstract: A method of isolating and purifying toxin conjugates using hydrophobic interaction chromatography. Crude conjugate mixtures are sized to remove unconjugated toxin, and loaded onto a column filled with a suitable hydrophobic gel. Elution is effected with salt solutions of decreasing ionic strength, which salt solutions optionally include increasing amounts of an organic solvent. Toxin conjugate substantially free of unconjugated Ig and unconjugated toxin is provided.

Abstract: Substantially pure, intracellularly produced, soluble recombinant ricin toxin A (RTA) is recovered from transformed cells by disrupting the cell membrane, removing insoluble cell membrane materials from the disruptate, adjusting the pH of the cell membrane material-free solution to 6 to 6.5 and the conductivity to 1.25 to 1.75 millisiemens, passing the adjusted solution through a bed of SP-cellulose cation exchanger, and eluting the substantially pure RTA from the bed.